Bis-Pro-5FU
Bis-Pro-5FU (Compound 4) is a 5-FU precursor that confers oral bioavailability and increase the safety profile of 5-Fluorouracil (5-FU) chemotherapy regimens. 5-FU is an antineoplastic antimetabolite that is widely used for the research of colorectal and pancreatic cancer.
For research use only. We do not sell to patients.
- CAS No.: 2155827-07-7
- Formula: C10H7FN2O2
- Molecular Weight:206.17
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| BXPC-3 | EC50 |
>100 μM
Compound: 4
|
Antiproliferative activity against human BxPC-3 cells assessed as reduction in cell viability measured after 5 days by PrestoBlue reagent based assay
Antiproliferative activity against human BxPC-3 cells assessed as reduction in cell viability measured after 5 days by PrestoBlue reagent based assay
|
[PMID: 34979089] |
| HCT-116 | EC50 |
>100 μM
Compound: 4
|
Antiproliferative activity against human HCT-116 cells assessed as reduction in cell viability measured after 5 days by PrestoBlue reagent based assay
Antiproliferative activity against human HCT-116 cells assessed as reduction in cell viability measured after 5 days by PrestoBlue reagent based assay
|
[PMID: 34979089] |
Chemical Information
-
CAS No. 2155827-07-7
-
Molecular Weight 206.17
-
Formula C10H7FN2O2
-
SMILES
FC1=CN=C(OCC#C)N=C1OCC#C
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Protocol for Pharmacokinetic Study
Pharmacokinetic studies quantify how an organism handles a drug over time through absorption, distribution, metabolism, and excretion, and the core experimental readout is the concentration-time profile of parent drug and, when relevant, metabolites in biological matrices such as plasma, whole blood, urine, bile, or tissue. Pharmacokinetic analysis links dose, route, exposure, clearance, half-life, distribution, bioavailability, and systemic exposure to drug efficacy and toxicity hypotheses rather than measuring a signaling pathway directly. The literature links pharmacokinetics to drug-development phenotypes by showing that drug metabolism and pharmacokinetics influence compound progression, exposure-response interpretation, safety margins, dosing strategy, and failure risk during discovery and development. DMPK science contributes to compound optimization by integrating physicochemical properties, in vitro metabolism, transporter behavior, in vivo exposure, and pharmacodynamic contex
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)